Profile
Randall L.
Halcomb was the founder of Terns Pharmaceuticals, Inc. (founded in 2017) where he held the title of SVP-Chemistry & Early Development from 2017 to 2019.
He also held former positions as Director-Medicinal Chemistry at Gilead Sciences, Inc., Vice President-Chemistry at Igenica Biotherapeutics, Inc., and Vice President-Medicinal Chemistry at Pliant Therapeutics, Inc. (2016-2017).
Dr. Halcomb received a doctorate degree from Yale University and an undergraduate degree from The University of Alabama.
Former positions of Randall L. Halcomb
| Companies | Position | End |
|---|---|---|
| TERNS PHARMACEUTICALS, INC. | Founder | 01/01/2019 |
| PLIANT THERAPEUTICS, INC. | Corporate Officer/Principal | 01/01/2017 |
| GILEAD SCIENCES, INC. | Corporate Officer/Principal | - |
Igenica Biotherapeutics, Inc.
Igenica Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops therapeutics for the treatment of cancer | Corporate Officer/Principal | - |
Training of Randall L. Halcomb
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 6 |
|---|---|
Gilead Sciences, Inc.
Gilead Sciences, Inc. BiotechnologyHealth Technology Discovers, develops and commercializes therapeutic products and treatments for life threatening diseases | Health Technology |
Igenica Biotherapeutics, Inc.
Igenica Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops therapeutics for the treatment of cancer | Health Technology |
Yale University
Yale University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The University of Alabama
The University of Alabama Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Pliant Therapeutics, Inc.
Pliant Therapeutics, Inc. BiotechnologyHealth Technology Operates as biopharmaceutical company focuses on discovering and developing novel therapies for the treatment of fibrosis | Health Technology |
Terns Pharmaceuticals, Inc.
Terns Pharmaceuticals, Inc. BiotechnologyHealth Technology Develops small-molecule product candidates to address serious diseases including oncology and obesity | Health Technology |
- Stock Market
- Insiders
- Randall L. Halcomb
















